Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

被引:57
作者
Satterlee, Andrew B. [1 ,2 ,3 ]
Rojas, Juan D. [3 ]
Dayton, Paul A. [3 ]
Huang, Leaf [1 ,2 ,3 ]
机构
[1] Univ North Carolina Chapel Hill, Eshelman Sch Pharm, Div Mol Pharmaceut, Chapel Hill, NC 27599 USA
[2] Univ North Carolina Chapel Hill, Ctr Nanotechnol Drug Delivery, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA
[3] UNC & NCSU Joint Dept Biomed Engn, Chapel Hill, NC 27599 USA
基金
美国国家科学基金会;
关键词
Cancer; Theranostic; Nanoparticle; CA4P; EPR; Desmoplastic; Cisplatin; COMBRETASTATIN A4 PHOSPHATE; HEPATOCELLULAR-CARCINOMA; LUNG-CANCER; CISPLATIN; EFFICACY; AGENTS; ULTRASOUND; PERFUSION; DELIVERY; POTENT;
D O I
10.7150/thno.16681
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment. We have developed a combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the accumulation and retention of nanoparticles in the tumor. The vascular disrupting agent Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is maintained over several days. We use ultrasound to measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic isotope (177)Lutetium as a therapeutic agent as well as a means to measure nanoparticle accumulation and retention in the tumor. This combination therapy induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and allowing further tumor growth inhibition using a cisplatin-containing nanoparticle.
引用
收藏
页码:253 / 269
页数:17
相关论文
共 30 条
[21]   A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging [J].
Satterlee, Andrew B. ;
Yuan, Hong ;
Huang, Leaf .
JOURNAL OF CONTROLLED RELEASE, 2015, 217 :170-182
[22]   Anti-tumor Effect of Integrin Targeted 177Lu-3PRGD2 and Combined Therapy with Endostar [J].
Shi, Jiyun ;
Fan, Di ;
Dong, Chengyan ;
Liu, Hao ;
Jia, Bing ;
Zhao, Huiyun ;
Jin, Xiaona ;
Liu, Zhaofei ;
Li, Fang ;
Wang, Fan .
THERANOSTICS, 2014, 4 (03) :256-266
[23]  
Siemann DW, 2009, EXPERT OPIN INV DRUG, V18, P189, DOI [10.1517/13543780802691068, 10.1517/13543780802691068 ]
[24]  
Siemann DW, 2005, CLIN CANCER RES, V11, P416
[25]   Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy [J].
Smith, Neil R. ;
Baker, Dawn ;
Farren, Matthew ;
Pommier, Aurelien ;
Swann, Ruth ;
Wang, Xin ;
Mistry, Sunita ;
McDaid, Karen ;
Kendrew, Jane ;
Womack, Chris ;
Wedge, Stephen R. ;
Barry, Simon T. .
CLINICAL CANCER RESEARCH, 2013, 19 (24) :6943-6956
[26]  
Sofou S, 2008, INT J NANOMED, V3, P181
[27]   Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions [J].
Song, Wantong ;
Tang, Zhaohui ;
Zhang, Dawei ;
Yu, Haiyang ;
Chen, Xuesi .
SMALL, 2015, 11 (31) :3755-3761
[28]  
Stein R, 2001, J NUCL MED, V42, P967
[29]   The biology of the combretastatins as tumour vascular targeting agents [J].
Tozer, GM ;
Kanthou, C ;
Parkins, CS ;
Hill, SA .
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2002, 83 (01) :21-38
[30]  
Wendt R, 2010, J NUCL MED, V51